Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126873) titled 'A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes' on Aug. 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: EndoCell Therapeutics, Inc.
Condition:
Diabetes Mellitus, Type 1
Impaired Hypoglycemic Awareness
Severe Hypoglycemia
Intervention:
Biological: Allogeneic Human E-islet (E-islet 01)
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 11, 2025
Target Sample Size: 21
Countries of Recruitment:
Ch...